

**REMARKS**

Prior to the present Office Action, claims 1-29 and 38-65 were pending. Applicants hereby cancel claims 39-65 without prejudice to further prosecution at a later date. Claims 66-81 are added. Therefore, claims 1-29, 38 and 66-81 are presently pending in this application.

5 The drawings are modified to add several element numbers and lead lines. Accordingly, a set of REPLACEMENT drawings with the changes made and an ANNOTATED set showing the change made are attached. Changes were only made in sheets 1, 5, 11-12, and 14.

10 A number of amendments have also been made to the specification, primarily consisting of insertion of text that was previously in the drawings in the parent application (S/N 10/562,964). Certain element numbers have also been added. Because of the number or amendments, a substitute specification (clean version) under 37 C.F.R. §1.125 is attached incorporating the amendments, along with a copy showing the amendments using cross-outs and interlineations as required. No new matter has been added.

The Office Action restricted the claims to the following groups:

- 15                   Group I (claims 1-29 and 38),  
                    Group II (claims 39-47), and  
                    Group III (claims 48-65).

20 Applicants elect Group I (claims 1-29 and 38) without traverse. Claims 1-29, 38 and 66-79 pertain to a method of securing a device to bodily tissue and an attaching means, and appear to read on the elected claims.

New claims 80 and 81 pertain to a method of securing an implantable injection port to bodily tissue, and are withdrawn pending allowance of a generic preceding claim.


Respectfully submitted,

25 Dated: October 19, 2009


/Stephen Donovan/  
Stephen Donovan  
Registration No. 33,433

30 Please send all inquiries and correspondence to:  
Patent Department  
Allergan, Inc. (T2-7H)  
2525 Dupont Drive  
Irvine, CA 92612  
35 Telephone: (714) 246-4026  
Facsimile: (714) 246-4249

14/40



12/40



11/40




FIG. 21





FIG. 20



1/40

